US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
DE69838552T2
(de)
*
|
1997-07-14 |
2008-05-21 |
Bolder Biotechnology, Inc., Louisville |
Derivate des wachstumshormons und verwandte proteine
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
EE04967B1
(et)
|
1998-10-16 |
2008-02-15 |
Biogen, Incorporated |
Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
PT1121382E
(pt)
|
1998-10-16 |
2006-10-31 |
Biogen Idec Inc |
Proteinas de fusao do interferao beta e as respectivas utilizacoes
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
AU3714800A
(en)
*
|
1999-03-02 |
2000-09-21 |
Schering Corporation |
Hiv therapy
|
US6923966B2
(en)
*
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
WO2001026677A1
(fr)
*
|
1999-10-12 |
2001-04-19 |
Santen Pharmaceutical Co., Ltd. |
Complexe a base d'interferon et son utilisation en medecine
|
YU32402A
(sh)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Konjugati gama interferona
|
CA2390292A1
(en)
*
|
1999-11-12 |
2001-05-25 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
AR027509A1
(es)
|
2000-01-10 |
2003-04-02 |
Maxygen Aps |
Conjugados g-csf
|
ES2325877T3
(es)
|
2000-02-11 |
2009-09-23 |
Bayer Healthcare Llc |
Moleculas de tipo factor vii o viia.
|
CA2402024A1
(en)
*
|
2000-03-09 |
2001-09-13 |
Schering Corporation |
Hiv immune adjuvant therapy
|
KR100353392B1
(ko)
*
|
2000-03-13 |
2002-09-18 |
선바이오(주) |
높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
|
US6476062B2
(en)
|
2000-03-30 |
2002-11-05 |
Schering Corporation |
Chemokine receptor antagonists
|
DE60116137T2
(de)
*
|
2000-05-16 |
2006-08-24 |
Lipoxen Technologies Ltd. |
Derivatisierung von proteinen in wässrigem lösungsmittel
|
AU2001280035A1
(en)
*
|
2000-07-26 |
2002-02-05 |
Ramot University Authority For Applied Research And Industrial Development Ltd. |
Intracellular delivery system for protein phosphatases and other polypeptides
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
AU2001273388B2
(en)
*
|
2000-09-08 |
2005-01-13 |
Gryphon Therapeutics, Inc. |
"Pseudo"-native chemical ligation
|
EP1324779B1
(de)
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegyliertes interleukin 10
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
EP1366075B1
(de)
|
2001-02-27 |
2009-05-27 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
WO2003037915A1
(en)
*
|
2001-10-31 |
2003-05-08 |
Biopolymed Inc. |
Biocompatible polymers including peptide spacer
|
KR100480430B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-베타와 폴리에틸렌글리콜 유도체의 배합체
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
JP2005517648A
(ja)
*
|
2001-12-07 |
2005-06-16 |
インターミューン インコーポレイテッド |
肝炎ウイルス感染症を治療するための組成物および方法
|
CN1630530A
(zh)
|
2002-01-18 |
2005-06-22 |
比奥根艾迪克Ma公司 |
聚亚烷基聚合物及其用途
|
WO2003078461A1
(en)
*
|
2002-03-20 |
2003-09-25 |
Biopolymed Inc. |
Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
|
ATE528014T1
(de)
|
2002-06-07 |
2011-10-15 |
Dyax Corp |
Polypeptid mit modifizierten kunitz domains
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
KR101186140B1
(ko)
|
2002-06-21 |
2012-09-27 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
페길화된 인자 vii 글리코형태
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
US7524931B2
(en)
*
|
2002-07-03 |
2009-04-28 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
SI2386310T1
(sl)
*
|
2002-08-28 |
2019-03-29 |
Dyax Corp. |
Metode za ohranjanje organov in tkiv
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
RU2005118752A
(ru)
*
|
2002-11-15 |
2006-02-10 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)
|
WO2004060300A2
(en)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
BR0317742A
(pt)
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de interferon-beta com potência biológica aumentada
|
US20050079155A1
(en)
*
|
2003-03-20 |
2005-04-14 |
Xencor, Inc. |
Generating protein pro-drugs using reversible PPG linkages
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
WO2004084948A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Biopolymed Inc. |
Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
|
US20050281778A1
(en)
*
|
2003-03-28 |
2005-12-22 |
Myung-Ok Park |
Human growth hormone conjugated with biocompatible polymer
|
JP4753867B2
(ja)
|
2003-04-15 |
2011-08-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
ヒトil−18を含むコンジュゲートおよびその置換変異体
|
EP1633317A4
(de)
|
2003-05-16 |
2008-08-20 |
Intermune Inc |
Synthetische chemokin-rezeptor-liganden und anwendungsverfahren dafür
|
CN100503628C
(zh)
|
2003-05-30 |
2009-06-24 |
法莫赛特股份有限公司 |
修饰的氟化核苷类似物
|
CN1863551A
(zh)
*
|
2003-07-31 |
2006-11-15 |
抗癌公司 |
用于提高在体内的效力的PLP和PEG-rMETase的用途
|
EP2263684A1
(de)
|
2003-10-10 |
2010-12-22 |
Novo Nordisk A/S |
IL-21 Derivate
|
AP2287A
(en)
|
2003-10-14 |
2011-10-31 |
Intermune Inc |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
|
EP2641611A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
US20050089952A1
(en)
*
|
2003-10-22 |
2005-04-28 |
Akzo Nobel N.V. |
Apparatuses and processes for increasing protein PEGylation reaction yields
|
WO2005040758A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20070258946A1
(en)
*
|
2003-12-23 |
2007-11-08 |
Blatt Lawrence M |
Combination Therapy for Treating Hepatitis C Virus Infection
|
WO2005070973A2
(en)
*
|
2004-01-21 |
2005-08-04 |
Nektar Therapeutics Al, Corporation |
Method of preparing propionic acid-terminated polymers
|
WO2005074650A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
JP2007526317A
(ja)
*
|
2004-03-01 |
2007-09-13 |
エンゾン ファーマスーティカルズ インコーポレイテッド |
インターフェロン−ベータ・ポリマー結合体
|
AU2005224078B2
(en)
|
2004-03-17 |
2011-01-27 |
Anticancer, Inc. |
Methods for increasing protein polyethylene glycol (PEG) conjugation
|
EP1586334A1
(de)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF Konjugate mit PEG
|
US20060018875A1
(en)
*
|
2004-06-14 |
2006-01-26 |
Blatt Lawrence M |
Interferon compositions and methods of use thereof
|
US20050281872A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Peter Summerville |
Enhanced compliance antiviral medicaments and methods of manufacture and use
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP2626368B1
(de)
|
2004-07-19 |
2016-12-21 |
Biocon Limited |
Insulinoligomerkonjugate, Formulierungen und Verwendungen davon
|
US7329737B2
(en)
|
2004-08-03 |
2008-02-12 |
Dyax Corp. |
Antibodies that bind hK-1
|
CN101039660B
(zh)
*
|
2004-08-12 |
2010-10-06 |
先灵公司 |
稳定的聚乙二醇化干扰素制剂
|
KR101177590B1
(ko)
|
2004-09-14 |
2012-08-27 |
파마셋 인코포레이티드 |
2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
CN101087875B
(zh)
|
2004-12-22 |
2012-08-22 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
BRPI0518661A2
(pt)
|
2004-12-22 |
2008-12-02 |
Ambrx Inc |
mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
EP1863519B1
(de)
|
2005-03-31 |
2013-09-25 |
The General Hospital Corporation |
Modulation von hgf/hgfr-aktivität zur behandlung von lymphödem
|
KR20080026135A
(ko)
|
2005-06-03 |
2008-03-24 |
암브룩스, 인코포레이티드 |
개선된 인간 인터페론 분자 및 이의 용도
|
EP1893632B1
(de)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
|
CN101257926A
(zh)
*
|
2005-08-04 |
2008-09-03 |
尼克塔治疗亚拉巴马公司 |
G-csf部分与聚合物的轭合物
|
CN101379086B
(zh)
|
2005-08-19 |
2013-07-17 |
惠氏公司 |
抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
|
EP2339014B1
(de)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
|
CU23556A1
(es)
*
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
KR101418607B1
(ko)
|
2006-01-12 |
2014-07-14 |
호쿠산 가부시키가이샤 |
인터페론 α를 포함하는 구강 조성물
|
ITMI20060612A1
(it)
*
|
2006-03-30 |
2007-09-30 |
Keryos Spa |
New activaded poly-ethylene glycols-and related polymers and their applications
|
CA2648077A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
CA2653748A1
(en)
|
2006-05-02 |
2007-11-15 |
Allozyne, Inc. |
Non-natural amino acid substituted polypeptides
|
AU2007253264A1
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Factor IX analogues having prolonged in vivo half life
|
US20070282170A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Sundaram Ravikumar |
Rake Retractor and Needle Assembly for Minimally Invasive Surgical Applications
|
US8008948B2
(en)
*
|
2006-07-06 |
2011-08-30 |
Denso Corporation |
Peak voltage detector circuit and binarizing circuit including the same circuit
|
EP1886685A1
(de)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
|
EP2054076A2
(de)
*
|
2006-08-21 |
2009-05-06 |
United Therapeutics Corporation |
Kombinationstherapie zur behandlung von virusinfektionen
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
MX2009002526A
(es)
|
2006-09-08 |
2009-04-16 |
Ambrx Inc |
Transcripcion de tarn supresor en celulas de vertebrados.
|
JP2010504979A
(ja)
*
|
2006-09-29 |
2010-02-18 |
カンジ,インコーポレイテッド |
遺伝子治療のための方法および組成物
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
PT2097068E
(pt)
|
2006-11-24 |
2013-10-23 |
Cadila Healthcare Ltd |
Formulações de conjugados de peg-interferão alfa
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
BRPI0810622A2
(pt)
|
2007-05-02 |
2020-10-13 |
Ambrx, Inc. |
polipeptídeos de interferon beta modificados e seus usos
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
CA2707840A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
EP2186830B1
(de)
*
|
2007-09-04 |
2012-03-07 |
Biosteed Gene Expression Tech. CO., LTD. |
Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
|
CA2698396C
(en)
*
|
2007-09-04 |
2014-01-21 |
Biosteed Gene Expression Tech. Co., Ltd. |
Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
|
RU2453332C2
(ru)
*
|
2007-10-16 |
2012-06-20 |
Байокон Лимитид |
Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
CN101918026B
(zh)
|
2007-11-20 |
2016-03-02 |
Ambrx公司 |
经修饰胰岛素多肽和其用途
|
JP5702150B2
(ja)
|
2008-02-08 |
2015-04-15 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾されているレプチンポリペプチドおよびそれらの使用
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
EP2307367B1
(de)
|
2008-07-08 |
2014-09-24 |
Board of Regents, The University of Texas System |
Neue hemmer der proliferation und aktivierung signalübertragender und transkriptionsaktivierender (stat) proteine
|
UA103774C2
(uk)
|
2008-07-23 |
2013-11-25 |
Амбркс, Інк. |
Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
|
MY156568A
(en)
*
|
2008-07-31 |
2016-03-15 |
Pharmaessentia Corp |
Peptide-polymer conjugates
|
US20110195912A1
(en)
*
|
2008-09-17 |
2011-08-11 |
Nektar Therapeutics |
Oligomer-Protease Inhibitor Conjugates
|
MX343802B
(es)
|
2008-09-26 |
2016-11-23 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
PL2379115T3
(pl)
|
2008-12-17 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Wytwarzanie i zastosowania mono- i di-peg il-10
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
HUE057244T2
(hu)
|
2010-01-06 |
2022-04-28 |
Takeda Pharmaceuticals Co |
Plazma kallikreint kötõ fehérjék
|
CA2791841C
(en)
|
2010-03-05 |
2023-01-03 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
HUE026235T2
(en)
|
2010-03-31 |
2016-06-28 |
Gilead Pharmasset Llc |
Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
|
EP2569331A1
(de)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptid-inhibitoren von vla4
|
RU2447083C1
(ru)
*
|
2010-07-20 |
2012-04-10 |
Закрытое Акционерное Общество "Биокад" |
НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MA34521B1
(fr)
|
2010-08-17 |
2013-09-02 |
Ambrx Inc |
Polypeptides de relaxine modifiés et leurs utilisations
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
TW201242974A
(en)
|
2010-11-30 |
2012-11-01 |
Gilead Pharmasset Llc |
Compounds
|
JP2014506257A
(ja)
|
2011-01-06 |
2014-03-13 |
ダイアックス コーポレーション |
血漿カリクレイン結合タンパク質
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
JP2014522641A
(ja)
|
2011-07-01 |
2014-09-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
リラキシン融合ポリペプチドおよびその使用
|
US20140314713A1
(en)
|
2011-07-20 |
2014-10-23 |
Universite Paris Diderot - Paris Vii |
Methods for determining treatment response in patients infected with hcv genotype 4
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
WO2013174988A1
(en)
|
2012-05-24 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
|
EP2859017B1
(de)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
KR101704893B1
(ko)
|
2012-06-15 |
2017-02-08 |
화이자 인코포레이티드 |
Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
|
EP2863955B1
(de)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
WO2014036492A1
(en)
|
2012-08-31 |
2014-03-06 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
EA023360B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
EA021643B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
EA021610B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Жидкое противовирусное лекарственное средство
|
EP2986306A4
(de)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
|
US9823255B2
(en)
|
2013-06-17 |
2017-11-21 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
MX2016002185A
(es)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|
JP6509867B2
(ja)
|
2013-08-30 |
2019-05-08 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためにインターロイキン−10を使用する方法
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
ES2862139T3
(es)
|
2013-11-11 |
2021-10-07 |
Armo Biosciences Inc |
Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
|
JP6719384B2
(ja)
|
2014-03-27 |
2020-07-15 |
ダイアックス コーポレーション |
糖尿病黄斑浮腫の治療のための組成物および方法
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
EP3620163A1
(de)
|
2014-05-01 |
2020-03-11 |
Eiger Biopharmaceuticals, Inc. |
Behandlung von hepatitis-delta-virusinfektion
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
RU2554761C1
(ru)
*
|
2014-05-13 |
2015-06-27 |
Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" |
Противоэнтеровирусное и иммуностимулирующее средство
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
KR101736870B1
(ko)
*
|
2014-08-20 |
2017-05-18 |
한국코러스 주식회사 |
인터페론 접합체를 포함하는 복합체 및 이의 제조방법
|
JP2017536098A
(ja)
|
2014-10-14 |
2017-12-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−15組成物及びその使用
|
KR20170084033A
(ko)
|
2014-10-22 |
2017-07-19 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
|
CN114805533A
(zh)
|
2014-10-24 |
2022-07-29 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
EA037151B1
(ru)
|
2014-11-06 |
2021-02-11 |
Фармаэссентия Корпорейшн |
Способ лечения с использованием пегилированного интерферона
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
DK3285768T3
(da)
|
2015-04-21 |
2021-01-25 |
Eiger Biopharmaceuticals Inc |
Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
|
CN107847583A
(zh)
|
2015-05-28 |
2018-03-27 |
阿尔莫生物科技股份有限公司 |
用于治疗癌症的聚乙二醇化白细胞介素‑10
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
JP7187315B2
(ja)
|
2015-11-04 |
2022-12-12 |
アイガー・バイオファーマシューティカルズ・インコーポレイテッド |
デルタ型肝炎ウイルス感染の処置
|
US11286307B2
(en)
|
2015-12-11 |
2022-03-29 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
WO2017181143A1
(en)
|
2016-04-15 |
2017-10-19 |
Generon (Shanghai) Corporation, Ltd. |
Use of il-22 in treating necrotizing enterocolitis
|
CN106539557A
(zh)
*
|
2016-10-08 |
2017-03-29 |
西安交通大学 |
一种基于恒速静脉输入的药代动力学参数的测定方法
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
JP7138350B2
(ja)
|
2016-11-14 |
2022-09-16 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. |
共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
|
EP3570849A1
(de)
|
2017-01-18 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von patienten mit myeloproliferativen erkrankungen
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
RU2678332C1
(ru)
|
2017-09-08 |
2019-01-28 |
Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") |
Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
|
PT3849614T
(pt)
|
2018-09-11 |
2024-02-28 |
Ambrx Inc |
Conjugados de polipeptídeos de interleucina-2 e suas utilizações
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
KR20220035365A
(ko)
|
2019-07-18 |
2022-03-22 |
엔요 파마 |
인터페론의 부작용을 감소시키는 방법
|
US20210285000A1
(en)
|
2020-03-05 |
2021-09-16 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
EP3912627B1
(de)
|
2020-05-20 |
2022-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von coronavirusinfektionen
|
TW202207950A
(zh)
|
2020-06-22 |
2022-03-01 |
美商詹森藥物公司 |
治療d型肝炎病毒感染之組合物及方法
|
EP3954393A1
(de)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
WO2022043496A2
(en)
|
2020-08-28 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of mait cells as biomarkers and biotargets in covid-19
|
WO2022079205A1
(en)
|
2020-10-15 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ifn-alpha polypeptides for the treatment of coronavirus infections
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|